These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 9990650)

  • 41. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.
    Rizos E; Bairaktari E; Kostoula A; Hasiotis G; Achimastos A; Ganotakis E; Elisaf M; Mikhailidis DP
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):127-34. PubMed ID: 12808486
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nebivolol: new therapy update.
    Sule SS; Frishman W
    Cardiol Rev; 2006; 14(5):259-64. PubMed ID: 16924166
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship between the sympatholytic action of nebivolol and hypotension.
    Ward JE; Coles P; Cox H; Eisenhofer G; Angus JA
    J Cardiovasc Pharmacol; 1992 Jul; 20(1):115-24. PubMed ID: 1383620
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer.
    Xhonneux R; Wouters L; Reneman RS; Janssen PA
    Eur J Pharmacol; 1990 Jun; 181(3):261-5. PubMed ID: 1974517
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy.
    Wisenbaugh T; Katz I; Davis J; Essop R; Skoularigis J; Middlemost S; Röthlisberger C; Skudicky D; Sareli P
    J Am Coll Cardiol; 1993 Apr; 21(5):1094-100. PubMed ID: 8096228
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study.
    Conraads VM; Metra M; Kamp O; De Keulenaer GW; Pieske B; Zamorano J; Vardas PE; Böhm M; Dei Cas L
    Eur J Heart Fail; 2012 Feb; 14(2):219-25. PubMed ID: 22147202
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
    Polónia J; Barbosa L; Silva JA; Bertoquini S
    Blood Press Monit; 2010 Oct; 15(5):235-9. PubMed ID: 20577082
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA
    Am J Hypertens; 2005 Dec; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient.
    Cockcroft J
    Vasc Health Risk Manag; 2007; 3(6):909-17. PubMed ID: 18200810
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Nebivolol: a beta blocker with vasodilator properties].
    Waeber B
    Praxis (Bern 1994); 2000 Apr; 89(15):631-3. PubMed ID: 10804847
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H; Lavie CJ; Ventura HO
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enantioselective pharmacokinetics and cardiovascular effects of nebivolol in L-NAME hypertensive rats.
    Bertera FM; Del Mauro JS; Lovera V; Chiappetta D; Polizio AH; Taira CA; Höcht C
    Hypertens Res; 2014 Mar; 37(3):194-201. PubMed ID: 24132009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nebivolol: a third-generation beta-adrenergic blocker.
    Veverka A; Nuzum DS; Jolly JL
    Ann Pharmacother; 2006; 40(7-8):1353-60. PubMed ID: 16822893
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effect of nebivolol on dynamics of microalbuminuria, renal blood flow and 24-hour blood pressure profile in patients with hypertension].
    Gromnatskiĭ NI; Vasil'eva DA
    Kardiologiia; 2002; 42(9):53-6. PubMed ID: 12494075
    [No Abstract]   [Full Text] [Related]  

  • 56. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension.
    Kamp O; Sieswerda GT; Visser CA
    Am J Cardiol; 2003 Aug; 92(3):344-8. PubMed ID: 12888152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension.
    Simon G; Johnson ML
    Clin Exp Hypertens; 1993 May; 15(3):501-9. PubMed ID: 8098243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of the selective beta 1-adrenoceptor antagonist, nebivolol, on cardiovascular parameters in the pithed normotensive rat.
    Schneider J; Fruh C; Wilffert B; Peters T
    Pharmacology; 1990; 40(1):33-41. PubMed ID: 1970437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular effects of dl-nebivolol and its enantiomers--a comparison with those of atenolol.
    Van de Water A; Xhonneux R; Reneman RS; Janssen PA
    Eur J Pharmacol; 1988 Oct; 156(1):95-103. PubMed ID: 3208842
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients.
    Himmelmann A; Hedner T; Snoeck E; Lundgren B; Hedner J
    Eur J Clin Pharmacol; 1996; 51(3-4):259-64. PubMed ID: 9010695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.